inhaled tobramycin — Competitive Intelligence Brief

inhaled tobramycin (inhaled tobramycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside antibiotic. Area: Infectious Disease / Pulmonology.

marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit Infectious Disease / Pulmonology Small molecule

Target snapshot

inhaled tobramycin (inhaled tobramycin) — Seattle Children's Hospital. Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, killing susceptible bacteria in the lungs.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
inhaled tobramycin TARGET	inhaled tobramycin	Seattle Children's Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Neomycin Oral Product	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
topical tetracycline	topical tetracycline	Johns Hopkins University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Doxycycline Hyclate Enteric-Coated Capsules	Doxycycline Hyclate Enteric-Coated Capsules	The Third Xiangya Hospital of Central South University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Omadacycline Injection	Omadacycline Injection	Wake Forest University Health Sciences	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside antibiotic class)

1. U.S. Army Medical Research and Development Command · 2 drugs in this class
2. Hospital General Universitario Elche · 2 drugs in this class
3. Murdoch Childrens Research Institute · 2 drugs in this class
4. Public Health Service of Amsterdam · 1 drug in this class
5. Seattle Children's Hospital · 1 drug in this class
6. Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
7. Shanghai Zhongshan Hospital · 1 drug in this class
8. South Australian Health and Medical Research Institute · 1 drug in this class
9. The University of Queensland · 1 drug in this class
10. University of Leipzig · 1 drug in this class